BIVV 009

Drug Profile

BIVV 009

Alternative Names: BIVV-009; TNT009

Latest Information Update: 14 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator True North Therapeutics
  • Developer Bioverativ; True North Therapeutics
  • Class Antianaemics; Monoclonal antibodies
  • Mechanism of Action Complement C1s inhibitors; Complement system protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Autoimmune haemolytic anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Autoimmune haemolytic anaemia; Bullous pemphigoid; Idiopathic thrombocytopenic purpura; Renal transplant rejection

Most Recent Events

  • 08 Aug 2017 Phase-I clinical trials in Idiopathic thrombocytopenic purpura in USA (IV) (NCT03275454)
  • 02 Aug 2017 Bioverativ plans a phase III trial for Autoimmune haemolytic anaemia in 2017
  • 28 Jun 2017 True North Therapeutics has been acquired and merged into Bioverativ
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top